

## ASX ANNOUNCEMENT

### Benitec raises additional A\$2.84 million with Share Purchase Plan

**Sydney Australia, 31 July 2013:** Benitec Biopharma Limited (ASX Code: BLT), today announced that it has closed a Share Purchase Plan for existing shareholders on 29 July 2013, raising \$2.84 million. These funds are additional to the \$7.90million raised in private placements announced in July 2013 and the \$0.98 million announced in March 2013. The combined proceeds from the private placements and the Share Purchase Plan total \$11.720 million. The allotment to participants in the Share Purchase Plan will be made on 6 August 2013.

The successful completion of this capital raise ensures the company has the funds in place to complete its first in-man trial (Phase I/IIa) for its Hepatitis C treatment, planned to commence later this year. In addition, Benitec will complete preclinical toxicology, biodistribution and dose-finding studies for Tribetarna™, its drug resistant non-small cell lung cancer (NSCLC) program, and conduct a European based Phase I/IIa clinical trial in drug resistant NSCLC patients which is planned to commence in Q4 CY14.

Benitec will also use the proceeds to manufacture clinical material for a potential second HCV clinical trial (based on outcomes from the first trial), as well as advance business development activities and pre-clinical studies in pipeline programs, and for general working capital.

Benitec's CEO Dr Peter French said, "We are very pleased with the broad support for the Share Purchase Plan. Over 440 shareholders contributed to the Share Purchase Plan, and this reflects confidence by shareholders in the Company to deliver on our strategy of taking our transformational gene silencing-based therapeutic technology into the clinic".

**For more information please contact:** Dr Peter French | Chief Executive Officer  
Phone: +61 (02) 9555 6986 | [pfrench@benitec.com](mailto:pfrench@benitec.com) | [www.benitec.com](http://www.benitec.com)

**About Benitec Biopharma Limited:** Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com).